**AI‑Enhanced Gene‑Expression Fingerprinting for Rapid Repurposing of Kinase Inhibitors in Neurodegenerative Disorders**

1. Introduction The pharmaceutical industry spends an estimated USD $2.5 bn annually on late‑stage failure, largely due to inefficiencies in target‑drug matching. Drug repurposing—identifying new indications for approved or investigational compounds—offers a cost‑effective alternative. Kinase inhibitors, already approved for oncology indications, present a rich chemical library with known pharmacokinetics and safety profiles...